AKBA Q3 2019 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$366M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$92M+73.0% YoY

Gross Profit

$54M58.4% margin

Operating Income

-$56M-60.8% margin

Net Income

-$55M-59.3% margin

EPS (Diluted)

$-0.46

QoQ Revenue Growth

-8.8%

Cash Flow

Operating Cash Flow

$11M

Free Cash Flow

$8M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$795M

Total Liabilities

$328M

Stockholders' Equity

$468M

Cash & Equivalents

$123M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$92M	$53M	+73.0%
Gross Profit	$54M	-$17M	+407.6%
Operating Income	-$56M	-$28M	-100.8%
Net Income	-$55M	-$26M	-109.6%

Revenue Segments

Product

$30M100%